As of 9 Nov 2026, Sanyou Biopharmaceuticals has raised $15.0M across 1 verified round on record (amounts in other currencies converted to USD); latest: nearly RMB 100 million Series C, announced 9 Nov 2026.
A high-tech biopharmaceutical company
sanyoubio.comShanghai, ChinaBiotechFounded 2015
4 sources · checked 2 times, last 1h ago
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series C | $15.0M $45M to date nearly RMB 100 million | 2026-11-09 | not stated | 4 outlets. #13 in Trending |
4 sources · checked 2 times, last 1h ago [ VERIFIED · CORRECTED ] read against 1 of 4 sources | ||||
Sanyou Bio is a high-tech biopharmaceutical company that develops and commercializes innovative drugs, using its AI-STAL antibody/molecule libraries and SAI-DA platform to help drug developers worldwide.
Sanyou is building an AI-driven, dry-lab/wet-lab drug-discovery stack around its AI-STAL super-trillion libraries and SAI-DA accelerator, aimed at shortening the path from target selection to drug candidates and IND applications. Its pages report more than 2,000 pharmaceutical and biotechnology relationships, over 1,000 drug-discovery and stage-specific projects, and more than 10 collaborative candidates reaching preclinical or clinical development, while the November 2026 Series C announcement describes nearly RMB 100 million of exclusive Zero2IPO backing for scaling that platform.
Checked against 8 sources today
Also named as backers in company research: LH Ventures, Montesy Investment, Grand Mount Capital, Seeking Capital, Haier Biomedical, Shanghai Liferiver Bio-Tech, Haier Financial Holdings, Zijin Hongyun Fund, Huatai Guoxin Fund, Huatai Zijin, Qianhai Beizeng Asset Management, Mr. Guohai Xia, Shenzhen Yanghe Biomedicine Industry Investment Co., Ltd.
| EARLIER ROUNDS FROM COMPANY RESEARCH · DEVELOPING | ||||
| Series B+ financing round | tens of millions of RMB | 2022-08-02 | Zijin Hongyun Fund, Huatai Guoxin Fund under Huatai Zijin | |